BR9815548A - Composição farmacêutica para administração em dose única diária para alteração de lipìdios num indivìduo sem causar hepatotoxicidade induzida por drogas, miopatia ou rabdomiólise, comprimido revestido para administração oral e método para administração de dita composição - Google Patents

Composição farmacêutica para administração em dose única diária para alteração de lipìdios num indivìduo sem causar hepatotoxicidade induzida por drogas, miopatia ou rabdomiólise, comprimido revestido para administração oral e método para administração de dita composição

Info

Publication number
BR9815548A
BR9815548A BR9815548-2A BR9815548A BR9815548A BR 9815548 A BR9815548 A BR 9815548A BR 9815548 A BR9815548 A BR 9815548A BR 9815548 A BR9815548 A BR 9815548A
Authority
BR
Brazil
Prior art keywords
composition
nicotinamide
methyl
administration
rhabdomyolysis
Prior art date
Application number
BR9815548-2A
Other languages
English (en)
Inventor
David J Bova
Josephine Dunne
Original Assignee
Kos Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kos Pharma Inc filed Critical Kos Pharma Inc
Publication of BR9815548A publication Critical patent/BR9815548A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<B>"COMPOSIçãO FARMACêUTICA PARA ADMINISTRAçãO EM DOSE úNICA DIáRIA PARA ALTERAçãO DE LIPìDIOS NUM INDIVìDUO SEM CAUSAR HEPATOTOXICIDADE INDUZIDA POR DROGAS, MIOPATIA OU RABDOMIóLISE, COMPRIMIDO REVESTIDO PARA ADMINISTRAçãO ORAL E MéTODO PARA ADMINISTRAçãO DE DITA COMPOSIçãO"<D> A presente invenção está relacionada com combinações farmacêuticas sólidas para administração por via oral administração por via oral compreendendo ácido nicotínico ou compostos do ácido nicotínico ou misturas dos mesmos numa forma de liberação prolongada e um inibidor de HMG-CoA redutase, que servem para alterar os níveis de lipídios em indivíduos sofrendo de, por exemplo, hiperlipidemia e arteriosclerose, sem causar hepatotoxicidade induzida por drogas, miopatia ou rabdomiólise. A presente invenção está também relacionada aos métodos de alteração de lipídios séricos em indivíduos para tratar, por exemplo, hiperlipidemia em hiperlipidêmicos, lipidemia em normolipidêmicos com diagnóstico ou predisposição a doenças cardiovasculares, e aretereoesclerose, administrando a referida composição farmacêutica sólida por via oral uma vez por dia como dose única durante o horário noturno, sem causar hepatotoxicidade induzida por drogas, miopatias ou rabdomiólise, ou sem causar, pelo menos num número apreciável de pacientes, hepatotoxicidade induzida por drogas, miopatias ou rabdomiólise de tal gravidade que imponha a suspensão do referido tratamento. Mais particularmente, a presente invenção diz respeito a composição farmacêutica sólida oral composta de, por exemplo, (1) um inibidor de HMG-CoA redutase para liberação imediata ou prolongada, (2) ácido nicotínico, um composto de ácido nicotínico ou misturas dos mesmos, e (3) um agente expansor para formar uma composição de liberação continuada para a liberação prolongada do ácido nicotínico ou composto de ácido nicotínico ou misturas dos mesmos para dosagem noturna ou vespertina para redução do percentual de lipídios séricos e aumento do colesterol HDL. De acordo com a presente invenção, e como forma de exemplo, apresenta-se uma composição para administração oral durante o horário noturno para alterar os lipídios séricos compreendendo ácido nicotínico e hidroxipropil metilcelulose na forma de um comprimido ou drágea de liberação prolongada ou continuada revestido de um revestimento composto de um inibidor de HMG-CoA redutase numa forma de liberação imediata. Também de acordo com a presente invenção, as composições farmacêuticas podem incluir um agente anti-inflamatório não-esteróidico para redução da capacidade do ácido nicotínico ou compostos de ácido nicotínico para provocar reações de rubor em indivíduos.
BR9815548-2A 1997-07-31 1998-07-31 Composição farmacêutica para administração em dose única diária para alteração de lipìdios num indivìduo sem causar hepatotoxicidade induzida por drogas, miopatia ou rabdomiólise, comprimido revestido para administração oral e método para administração de dita composição BR9815548A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90375297A 1997-07-31 1997-07-31
PCT/US1998/015990 WO1999006035A2 (en) 1997-07-31 1998-07-31 COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT

Publications (1)

Publication Number Publication Date
BR9815548A true BR9815548A (pt) 2000-11-07

Family

ID=25418027

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815548-2A BR9815548A (pt) 1997-07-31 1998-07-31 Composição farmacêutica para administração em dose única diária para alteração de lipìdios num indivìduo sem causar hepatotoxicidade induzida por drogas, miopatia ou rabdomiólise, comprimido revestido para administração oral e método para administração de dita composição

Country Status (17)

Country Link
US (3) US20040053975A1 (pt)
EP (2) EP1792616B1 (pt)
JP (2) JP4870869B2 (pt)
AT (2) ATE359785T1 (pt)
AU (1) AU752673B2 (pt)
BR (1) BR9815548A (pt)
CA (1) CA2298549C (pt)
CY (1) CY1107057T1 (pt)
DE (2) DE69837610T2 (pt)
DK (1) DK1017390T3 (pt)
ES (2) ES2336492T3 (pt)
HK (1) HK1106153A1 (pt)
IL (2) IL134271A0 (pt)
NO (1) NO20000439L (pt)
NZ (1) NZ520176A (pt)
PT (1) PT1017390E (pt)
WO (1) WO1999006035A2 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE970731A1 (en) † 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
DE19858789A1 (de) * 1998-12-18 2000-06-21 Bayer Ag Kombination von Cerivastatin und Fibraten
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
WO2001005408A1 (en) * 1999-07-14 2001-01-25 Geltex Pharmaceuticals, Inc. Fat-binding polymers, optionally combined with lipase inhibitors
JP2001131151A (ja) * 1999-11-02 2001-05-15 Shionogi & Co Ltd オレフィン誘導体の新規用途
IL139450A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
EP1296672B2 (en) † 2000-06-09 2018-10-24 LEK Pharmaceuticals d.d. Stable pharmaceutical product and formulation
CN1250212C (zh) * 2000-10-23 2006-04-12 三共株式会社 血中脂类改善剂组合物
US6916849B2 (en) 2000-10-23 2005-07-12 Sankyo Company, Limited Compositions for improving lipid content in the blood
CA2428204A1 (en) 2000-11-07 2002-05-16 Sankyo Company, Limited Lipid peroxide-lowering compositions
TWI284529B (en) * 2000-12-18 2007-08-01 Sankyo Co A composition for lowering triglyceride
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
CA2494801A1 (en) * 2002-08-02 2004-02-12 Sankyo Company Limited Medicinal composition containing hmg-coa reductase inhibitor
JP4607436B2 (ja) * 2002-08-02 2011-01-05 第一三共株式会社 ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物
CN100415235C (zh) * 2002-08-02 2008-09-03 三共株式会社 含有HMG-CoA还原酶抑制剂的药物组合物
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
JP2007501217A (ja) * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク コレステリルエステル転送タンパク質阻害剤を制御放出し、そしてＨＭＧ−ＣｏＡレダクターゼ阻害剤を即時放出する投薬形態
EP1684704A2 (en) * 2003-10-29 2006-08-02 Raif M. Tawakol Compositions and methods for increasing hdl and hdl-2b levels
EP1877054A2 (en) * 2005-03-30 2008-01-16 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20070021379A1 (en) * 2005-07-11 2007-01-25 Pharmena North America Inc. Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities
KR20070063350A (ko) * 2005-12-14 2007-06-19 주식회사종근당 서방형 방출층과 속방형 방출층을 포함한 고지혈증 및동맥경화를 치료를 위한 약제학적 조성물
CA2569776A1 (en) * 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
WO2007103557A2 (en) * 2006-03-09 2007-09-13 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023958A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
DE102007003524A1 (de) * 2007-01-19 2008-09-04 MEDICE Arzneimittel Pütter GmbH & Co. KG Arzneimittel zur Behandlung und/oder Prävention von Arteriosklerose
KR100885029B1 (ko) 2007-02-07 2009-02-23 지엘팜텍 주식회사 경구투여용 서방성 삼중정제
WO2009016577A2 (en) * 2007-07-27 2009-02-05 Ranbaxy Laboratories Limited A pharmaceutical composition comprising atorvastatin and niacin
KR101164300B1 (ko) * 2008-02-22 2012-07-09 한올바이오파마주식회사 약제학적 제제
KR20090091075A (ko) * 2008-02-22 2009-08-26 한올제약주식회사 심혈관계 질환 치료용 약제학적 제제
JP2011512406A (ja) * 2008-02-22 2011-04-21 ハナル バイオファーマ カンパニー リミテッド 複合製剤
JP2011521915A (ja) * 2008-05-20 2011-07-28 セレニス セラピューティクス エス．エー． ナイアシン及びｎｓａｉｄ併用療法
RU2010153904A (ru) * 2008-06-02 2012-07-20 Др. Редди'С Лабораторис Лтд. (In) Ниацин-содержащие композиции с модифицированным высвобождением
TR201009949T1 (tr) * 2008-06-02 2011-03-21 Dr. Reddy's Laboratories, Ltd. Salımı değiştirilmiş niasin formülasyonları.
US20100178341A1 (en) * 2008-06-11 2010-07-15 Ranbaxy Laboratories Limited BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR
US8541435B2 (en) 2008-07-11 2013-09-24 Uday Saxena Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of Alzheimer's disease (AD)
MX345942B (es) * 2009-05-01 2017-02-27 Adare Pharmaceuticals Inc Composiciones de tabletas que se desintegran oralmente que comprenden combinaciones de farmacos en dosis alta y baja.
CA2706270C (en) * 2010-06-03 2020-01-07 Accucaps Industries Limited Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
ES2643693T3 (es) 2011-05-20 2017-11-23 Astrazeneca Uk Limited Composición farmacéutica de rosuvastatina cálcica
JP2017533973A (ja) 2014-11-14 2017-11-16 ジェムフィアー セラピューティクス インコーポレイテッド α，ω−ジカルボン酸末端ジアルカンエーテルを調製するためのプロセスおよび中間体
AU2016348638A1 (en) * 2015-11-06 2018-06-07 Gemphire Therapeutics Inc. Gemcabene combinations for the treatment of cardiovascular disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524001A (en) * 1965-03-04 1970-08-11 Upjohn Co Compositions and method for reducing free fatty acid and cholesterol in the blood of mammals with 3,5 - disubstituted isoxazoles
JPS63310827A (ja) * 1987-06-15 1988-12-19 Sanwa Kagaku Kenkyusho Co Ltd ニコチン酸誘導体を主剤とする徐放性製剤
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
US4933165A (en) * 1989-01-18 1990-06-12 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
CA2018470A1 (en) * 1989-07-17 1991-01-17 Scott Adams Biller Phosphorus-containing squalene synthetase inhibitors and method
WO1993009777A1 (en) * 1991-11-22 1993-05-27 Lipogenics, Inc. Tocotrienols and tocotrienol-like compounds and methods for their use
US5135935A (en) * 1991-05-17 1992-08-04 Merck & Co., Inc. Squalene synthetase inhibitors
US5840339A (en) * 1991-07-30 1998-11-24 Kunin; Robert Blood cholesterol reducing pharmaceutical composition
US5292534A (en) * 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
AU5787996A (en) * 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
US5773453A (en) * 1995-04-19 1998-06-30 Vanderbilt University Methods for administration of antilipemic drugs

Also Published As

Publication number Publication date
ES2283067T3 (es) 2007-10-16
WO1999006035A3 (en) 1999-04-22
US20040053975A1 (en) 2004-03-18
AU752673B2 (en) 2002-09-26
JP2001511444A (ja) 2001-08-14
CA2298549A1 (en) 1999-02-11
HK1106153A1 (en) 2008-03-07
DE69841395D1 (de) 2010-01-28
DK1017390T3 (da) 2007-06-11
EP1017390B1 (en) 2007-04-18
IL134271A0 (en) 2001-04-30
NO20000439D0 (no) 2000-01-27
PT1017390E (pt) 2007-07-24
EP1792616B1 (en) 2009-12-16
ATE451926T1 (de) 2010-01-15
CY1107057T1 (el) 2012-10-24
EP1017390A2 (en) 2000-07-12
ES2336492T3 (es) 2010-04-13
WO1999006035A2 (en) 1999-02-11
NO20000439L (no) 2000-03-22
US20120164221A1 (en) 2012-06-28
NZ520176A (en) 2005-02-25
EP1792616A1 (en) 2007-06-06
DE69837610T2 (de) 2008-01-03
AU8680198A (en) 1999-02-22
DE69837610D1 (de) 2007-05-31
JP2009235105A (ja) 2009-10-15
IL134271A (en) 2006-07-05
ATE359785T1 (de) 2007-05-15
US20090226518A1 (en) 2009-09-10
JP4870869B2 (ja) 2012-02-08
CA2298549C (en) 2006-01-10

Similar Documents

Publication Publication Date Title
BR9815548A (pt) Composição farmacêutica para administração em dose única diária para alteração de lipìdios num indivìduo sem causar hepatotoxicidade induzida por drogas, miopatia ou rabdomiólise, comprimido revestido para administração oral e método para administração de dita composição
IE970731A1 (en) Product and method for the treatment of hyperlipidemia
Smith et al. RP 73163: A bioavailable alkylsulphinyl-diphenylimidazole ACAT inhibitor
CA2382919A1 (en) Bicyclic imidazo-3-yl-amine derivatives
FR2684876B1 (fr) Compositions pharmaceutiques stabilisees comprenant un compose inhibiteur de la hmg-coa reductase et procede pour leur preparation.
CA2192899A1 (en) Composition containing l-carnitine and hydroxycitric acid
BR9607862A (pt) Composição farmacêutica filmogênica para administração transdérmica
CA2315927A1 (en) Oral pharmaceutical pulsed release dosage form
AU2681300A (en) Solid oral dosage form containing an enhancer
UY24288A1 (es) Procedimiento para la preparación de una composición de liberación retardada de paroxetina
EP0773022A3 (de) Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure
MX2007007843A (es) Formulacion de complejo de inhibidor de 3-hidroxi-3-metil glutaril coa reductasa y agente antihipertensivo, y proceso para su preparacion.
AU7915898A (en) Pharmaceutical composition in form of solid lipidic microparticles suitable to parenteral administration
CA2380087A1 (en) Beta-carboline drug products
WO1999012570A3 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2344053A1 (en) Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases
CA2303291A1 (en) Fatty acids as a diet supplement
HUP0004900A3 (en) Pharmaceutical compositions for treating disease-related or drug-induced dyskinesias containing piperidine derivatives as nmda receptor antagonist as active ingredient
AU1435888A (en) Binder-free granules with delayed release of the active compound
CA2511595A1 (en) Optically active dihydropyridine derivative
AU4732096A (en) Remedy for pulmonary heart
Bailey et al. Quinidine interaction with nifedipine and felodipine: pharmacokinetic and pharmacodynamic evaluation
AU2003296740A1 (en) Enantiomer-pure (4s,8s)- and (4r, 8r)-4-p-nitrobenzyl-8-methyl-3, 6, 9-triaza-3n, 6n, 9n-tricarboxymethyl-1, 11-undecanoic acid and derivatives thereof, method for producing them, and their use for producing pharmaceutical agents
WO2000064427A3 (en) Lamivudine containing pharmaceutical formulation
WO2002006299A3 (en) Therapeutic uses for aminosterol compounds

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: KOS LIFE SCIENCES, INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE E TAXA DE RESTAURACAO DA 4A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/455, A61K 31/465, A61K 9/20, A61K 9/16, A61K 31/455, A61K 9/20, A61K 9/24, A61K 9/48, A61K 31/785, A61K 45/06, A61P 3/06, A61P 9/10, A61K 9/16, A61K 31/455, A61K 9/20, A61K 9/24, A61K 9/48, A61K 31/74, A61K 45/00, A61P 3/00, A61P 9/00

Ipc: A61K 31/455 (2008.04), A61K 31/465 (2008.04), A61K

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]